AU2003255337A1 - Use of genes identified to be involved in tumor development for the development of anti-cancer drugs - Google Patents

Use of genes identified to be involved in tumor development for the development of anti-cancer drugs

Info

Publication number
AU2003255337A1
AU2003255337A1 AU2003255337A AU2003255337A AU2003255337A1 AU 2003255337 A1 AU2003255337 A1 AU 2003255337A1 AU 2003255337 A AU2003255337 A AU 2003255337A AU 2003255337 A AU2003255337 A AU 2003255337A AU 2003255337 A1 AU2003255337 A1 AU 2003255337A1
Authority
AU
Australia
Prior art keywords
development
involved
cancer drugs
genes identified
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003255337A
Other languages
English (en)
Other versions
AU2003255337A8 (en
Inventor
Antonius Jozef Maria Berns
John Paul De Koning
Jack Richard Lenz
Anders Henrik Lund
Carla Pedro Martins
Henricus Martinus Maria Mikkers
Maarten Matthijs Sharif Van Lohuizen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kylix BV
Original Assignee
Kylix BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP20020078143 external-priority patent/EP1386639A1/fr
Priority claimed from US10/224,524 external-priority patent/US20040033974A1/en
Application filed by Kylix BV filed Critical Kylix BV
Publication of AU2003255337A1 publication Critical patent/AU2003255337A1/en
Publication of AU2003255337A8 publication Critical patent/AU2003255337A8/xx
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/7056—Lectin superfamily, e.g. CD23, CD72
    • C07K14/70564—Selectins, e.g. CD62
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/01—Phosphotransferases with an alcohol group as acceptor (2.7.1)
    • C12Y207/01037—Protein kinase (2.7.1.37)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2003255337A 2002-07-31 2003-07-31 Use of genes identified to be involved in tumor development for the development of anti-cancer drugs Abandoned AU2003255337A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP20020078143 EP1386639A1 (fr) 2002-07-31 2002-07-31 Identification de 78 gènes impliqués dans le développement de tumeurs et leur utilisation pour le développement de drogues anticancéreuses et le diagnostic du cancer
EP02078143.1 2002-07-31
US10/224,524 2002-08-19
US10/224,524 US20040033974A1 (en) 2002-08-19 2002-08-19 Use of genes identified to be involved in tumor development for the development of anti-cancer drugs
PCT/EP2003/008470 WO2004012817A2 (fr) 2002-07-31 2003-07-31 Utilisation des genes identifies comme etant impliques dans la croissance tumorale, destinee au developpement de medicaments anticancereux

Publications (2)

Publication Number Publication Date
AU2003255337A1 true AU2003255337A1 (en) 2004-02-23
AU2003255337A8 AU2003255337A8 (en) 2004-02-23

Family

ID=31497090

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003255337A Abandoned AU2003255337A1 (en) 2002-07-31 2003-07-31 Use of genes identified to be involved in tumor development for the development of anti-cancer drugs

Country Status (2)

Country Link
AU (1) AU2003255337A1 (fr)
WO (1) WO2004012817A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101228274A (zh) * 2005-04-12 2008-07-23 布鲁塞尔大学 靶向半乳凝素-1的基于RNAi的方法用于治疗癌症的用途
SG157299A1 (en) * 2008-05-09 2009-12-29 Agency Science Tech & Res Diagnosis and treatment of kawasaki disease
EP3202783A1 (fr) * 2016-02-02 2017-08-09 Ecole Polytechnique Fédérale de Lausanne (EPFL) Cellules présentant des antigènes modifiés et leurs utilisations
MX2020008581A (es) 2018-02-21 2020-09-21 Bristol Myers Squibb Co Oligonucleotidos antisentido de la proteina cinasa del tipo ii delta dependiente del calcio/calmodulina (camk2d) y sus usos.

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994010309A1 (fr) * 1992-10-23 1994-05-11 Genetics Institute, Inc. Nouvelle proteine de ligand de p-selectine
KR100523506B1 (en) * 1995-08-03 2005-10-24 Peptide and O-glycan inhibitors of selectin mediated inflammation
WO2000078961A1 (fr) * 1999-06-23 2000-12-28 Genentech, Inc. Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides
US6165461A (en) * 1998-04-14 2000-12-26 Board Of Regents, University Of Texas System Tao protein kinases and methods of use therefor
WO2000058473A2 (fr) * 1999-03-31 2000-10-05 Curagen Corporation Acides nucleiques comprenant des phases de lecture ouverte codant des polypeptides; «orfx»
WO2001073028A2 (fr) * 2000-03-24 2001-10-04 Genetics Institute, Llc Nouvelle proteine de liaison aux ligands de glycoproteine p-selectine (psgl-1) et ses utilisations
AU2002220920A1 (en) * 2000-12-08 2002-06-18 Oxford Biomedica (Uk) Limited Method for identification of genes involved in specific diseases
US20030232334A1 (en) * 2000-12-22 2003-12-18 Morris David W. Novel compositions and methods for cancer
AU2002256359A1 (en) * 2001-04-24 2002-11-05 Epigenesis Pharmaceuticals, Inc. Antisense and anti-inflammatory based compositions to treat respiratory disorders
US8003315B2 (en) * 2001-12-13 2011-08-23 Exelixis, Inc. TAOJIKs as modifiers of the beta-catenin pathway and methods of use

Also Published As

Publication number Publication date
WO2004012817A3 (fr) 2004-10-28
WO2004012817A2 (fr) 2004-02-12
AU2003255337A8 (en) 2004-02-23

Similar Documents

Publication Publication Date Title
SI3296407T1 (sl) Mutacije gena PIK3CA pri rakih pri ljudeh
IL164463A (en) Use of osteoprotegerin in the preparation of medicaments
GB0418328D0 (en) Cancer methods and medicaments
AU2003238772A1 (en) In vitro evaluation of nucleic acid ligands
AU2003205913A1 (en) Materials and methods relating to cancer diagnosis
PL376971A1 (pl) Amplifikowane geny związane z rakiem
EP1635764A4 (fr) Conjugue destine au ciblage specifique d'agents anticancereux sur des cellules cancereuses, et production du conjugue
IL184008A0 (en) 4-cycloalkyl-substituted tetrahydrochinoline derivatives and use thereof as medicaments
DK1599573T3 (da) Model til at studere genernes rolle i tumorresistens over for kemoterapi
PT1803456E (pt) Composições farmacêuticas que compreendem l-733060 para utilização no tratamento de tumores cancerígenos
AU2003255337A1 (en) Use of genes identified to be involved in tumor development for the development of anti-cancer drugs
AU2006251169A8 (en) Tetrahydropyridothiophenes for use in the treatment of cancer
AU2003271016A1 (en) Use of n-acetyl-d-aminoglycosamine in preparation of drugs for the treatment of cacer and metastasis
AU2003900495A0 (en) Aroylhydrazone derivatives and therapeutic uses thereof
AU2003240997A1 (en) Complexes for the delivery of biologically-active material to cells
HK1089204A (en) Model for studying the role of genes in tumor resistance to chemotherapy
PL382844A1 (pl) Związki i ich zastosowanie do specyficznego i równoczesnego hamowania genów zaangażowanych w chorobach i odpowiednie leki
GB0312844D0 (en) Use of compounds in medicine
ZA200704650B (en) 4-cycloalkyl-substituted tetrahydrochinoline derivatives and use thereof as medicaments
AU2003304172A1 (en) The pharmaceutical use of total glucide of peony
IL175774A0 (en) Use of siramesine in the treatment of cancer
AU2003211983A1 (en) Drugs to be used in organ transplantation
AU2003227893A1 (en) Assay methods relating to the action of geminin in the licensing of dna replication complexes in transformed cells
GB0409144D0 (en) Materials and methods relating to the diagnosis of cancer
GB0414584D0 (en) Improvements realting to the administration of materials through the skin

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase